In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zimmer Biomet Holdings Inc.

www.zimmer.com

Latest From Zimmer Biomet Holdings Inc.

Into 2019: Meaningful Innovation In Medtech Is Reaching A 10-Year Peak

Medtech continues to outperform biotech from a sustainable investment growth point of view, and meanwhile medtech CEOs are on message about advancing value- and outcomes-based models with their provider partners. It all points to medtech being in a good place for 2019, and there is no reason for M&A and industry consolidation to stop anytime soon, says Jefferies equity analyst Raj Denhoy.

Financing M & A

BoneSupport Encouraged By Top-Line Data From CERTiFy Trial Of Cerament Bone Void Filler Injectable

Results of the CERTiFy study demonstrate Bonesupport's Cerament bone-void filler is non-inferior to autograft in treating tibia plateau fracture defects. The company says the study marks a major milestone for its business and will change the standard of care for this kind of injury.

Clinical Trials Orthopedics

Brexit No Certain Thing For European Medtech Groups Desperate To Plan Futures

Medtech stakeholders were reminded at the UK's largest regulatory forum that, for business in general, and medical technology manufacturers in particular, those willing to make the best of Brexit are still having to work in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.

Brexit Market Access

Brexit + MDR Equals Little Certainty For UK And EU Medtech Groups

Medtech stakeholders were reminded recently at the UK's largest regulatory forum that even those willing to make the best of Brexit are still working in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.

Brexit Market Access
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register